Advanced practice pharmacists in the field of diabetes work collaboratively with patients' medical providers, often in primary care settings or in close proximity to the providers' practices. They help to integrate the pharmaceutical, medical, education/ counseling, and direct patient care activities necessary to meet patients' individual self-management and diabetes care needs.
Patient education and self-management behavioral change are underpinnings of pharmaceutical care, and not only as they directly relate to the use of medications. Pharmacists, especially those who are certified diabetes educators (CDEs), frequently provide diabetes patients with education not only on medications, but also on the overall disease state, nutrition, physical activity, decision-making skills, psychosocial adaptation, complication prevention, goal setting, barrier resolution, and cost issues.
In addition to these substantial education responsibilities, advanced practice pharmacists who are Board Certified-Advanced Diabetes Managers (BC-ADMs) play an expanded role that encompasses disease state management. This includes performing clinical assessments and limited physical examinations; recognizing the need for additional care; making referrals as needed; ordering and interpreting specific laboratory tests; integrating their pharmacy patient care plans into patients' total medical care plans; and entering notes on patient charts or carrying out other forms of written communication with patients' medical care providers. Depending on state regulations and physician-based protocols, some advanced practice pharmacists can prescribe and adjust medications independently or after consultation with prescribing clinicians.
The clinical activities of BC-ADM pharmacists are not carried out independent of referring, collaborative practitioners. Rather, they are complementary to and serve to enhance the diagnostic, complex physical assessment, and management skills of medical providers.
The following case study illustrates the pharmacotherapeutic challenges of diabetes with other comorbidities, which can lead to potential drug-drug and drug-disease interactions. Although it does not offer detailed solutions to such problems, this case does describe the process of patient care and problem resolution as approached by advanced practice pharmacists.
Case Presentation
B.L. is a 58-year-old white woman who has been referred to the pharmacist clinician for pharmacotherapy assessment and diabetes management. Her multiple medical conditions include type 2 diabetes diagnosed in 1995, hypertension, hyperlipidemia, asthma, coronary artery disease, persistent peripheral edema, and longstanding musculoskeletal pain secondary to a motor vehicle accident. Her medical history includes atrial fibrillation with cardioversion, anemia, knee replacement, and multiple emergency room (ER) admissions for asthma.
B.L.'s diabetes is currently being treated with a premixed preparation of 75% insulin lispro protamine suspension with 25% insulin lispro preparation (Humalog 75/25), 33 units before breakfast and 23 units before supper.
She says she occasionally "takes a little more" insulin when she notes high blood glucose readings, but she has not been instructed on the use of an insulin adjustment algorithm.
Her other routine medications include the fluticasone metered dose inhaler (Flovent MDI), two puffs twice a day; salmeterol MDI (Serevent MDI), two puffs twice a day; naproxen (Naprosyn), 375 mg twice a day; enteric-coated aspirin, 325 mg daily; rosiglitazone (Avandia), 4 mg daily; furosemide (Lasix), 80 mg every morning; diltiazem (Cardizem CD), 180 mg daily (per cardiologist consult); lanoxin (Digoxin), 0.25 mg daily (per cardiologist consult); potassium chloride, 20 mEq daily; and fluvastatin (Lescol), 20 mg at bedtime. Medications she has been prescribed to take "as needed" include sublingual nitroglycerin for chest pain (has not been needed in the past month); furosemide, additional 40 mg later in the day if needed for swelling (on most days the additional dose is needed); and albuterol MDI (Proventil, Ventolin), two to four puffs every 4-6 hours for shortness of breath. She denies use of nicotine, alcohol, or recreational drugs; has no known drug allergies; and is up to date on her immunizations.
B.L.'s chief complaint now is increasing exacerbations of asthma and the need for prednisone tapers. She reports that during her last round of prednisone therapy, her blood glucose readings increased to the range of 300-400 mg/dl despite large decreases in her carbohydrate intake. She reports that she increases the frequency of her fluticasone MDI, salmeterol MDI, and albuterol MDI to four to five times/day when she has a flareup. However, her husband has been out of work for more than a year, and their only source of income is her Social Security check. Therefore, she has been unable to purchase the fluticasone or salmeterol and so has only been taking prednisone and albuterol for recent acute asthma exacerbations.
B.L. reports eating three meals a day with a snack between supper and bedtime. Her largest meal is supper. She states that she counts her carbohydrate servings at each meal and is "watching what she eats." She has not been able to exercise routinely for several weeks because of bad weather and her asthma.
The memory printout from her blood glucose meter for the past 30 days shows a total of 53 tests with a mean blood glucose of 241 mg/dl (SD 74). With a premeal glucose target set at 70-140 mg/dl, there were no readings below target, 8% within target, and 91% above target. By comparison, her results from the same month 1 year ago averaged 112 mg/dl, with a high of 146 mg/dl and a low of 78 mg/dl. 
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Outcomes and Endpoints
Clinical outcomes are distinctly different from therapeutic or interventional endpoints. The former refers to the impact of treatment on patients' overall medical status and quality of life and should emphasize patient-oriented evidence that matters (POEMs) rather than disease-oriented evidence (DOEs). Therapeutic endpoints include the anticipated and desired clinical effects from drug therapy that are expected, ultimately, to achieve the desired outcome(s). As such, therapeutic endpoints are used as surrogate markers for achievement of outcomes. Commonly, more than one endpoint will be needed to achieve an outcome. For example, near-normal glycemic control and normalization of blood pressure (endpoints) would be necessary to significantly reduce the risk of end-stage renal disease (outcome).
Therapeutic endpoints should be specific, measurable, and achievable within a short period of time. Achievement of clinical outcomes usually cannot be determined except by long-term observation or retrospective analysis.
Outcomes and endpoints for any given patient should be determined collaboratively between patient and provider before selecting or initiating pharmacotherapy or nonpharmacological interventions. Taking the time to identify these components up front (and periodically revise them later on) helps ensure that subsequent medications or strategies are appropriately directed. It further ensures a common vision and commitment for ongoing patient care and self-management among the care team (including the patient), thus maximizing the potential for optimal disease control and patient satisfaction.
The outcomes and endpoints for a patient such as B.L. are numerous and obviously would not be addressed or attained in a single session. Therefore, after desired outcomes and endpoints are determined, they should be prioritized according to medical urgency and patient preference. Implementation and goal setting related to these priorities can then be undertaken, thus establishing a treatment plan for the eventual attainment of the full list.
During ongoing and follow-up visits, this care plan should be reviewed and modified as indicated by changes in patient status, preferences, and medical findings. Examples of desired outcomes and endpoints for B.L. are given in Tables 1 and 2 . For the sake of brevity, these tables are not intended to be inclusive.
Medication-Related Problems and Proposed Interventions
With agreement between patient and clinician concerning desired outcomes and endpoints, the next logical step is to evaluate whether the current treatment plan is likely to achieve those goals, or, if treatment is to be initiated, which therapies or interventions should be selected.
According to Strand et al., 1 a medication-related problem is any aspect of a patient's drug therapy that is interfering with a desired, positive patient (therapeutic) outcome or endpoint. The PWDT proposes a systematic and comprehensive method to identify, resolve, or prevent medication-related problems based on the following major categories: 1. No indication for a current drug 2. Indication for a drug (or device or intervention) but none prescribed 1. Mortality outcomes a. Avoid respiratory, cardiovascular, thromboembolic, or diabetes-related premature death.
• Life expectancy, American females: 79.4 years 5 2. Morbidity outcomes a. Disease-related: Reduce morbidity resulting from uncontrolled blood glucose, blood pressure, dyslipidemia, and cardiovascular disease.
• Retard the progression of disease.
• Prevent, recognize, and treat early any complications of chronic conditions, such as neuropathy (autonomic or peripheral), eye disease (e.g., retinal vascular narrowing, hemorrhages, exudates, papilledema), cardiac disease (e.g., left ventricular hypertrophy, congestive heart failure, myocardial infarction), nephropathy (e.g., proteinuria, nephrosclerosis), and lower-leg amputation.
• Prevent chronic symptoms of asthma (e.g., coughing or breathlessness at night, in the early morning, or after exertion).
• Retain recognition of hypoglycemia symptoms.
• Maintain near-normal lung function.
• Maintain normal activity levels (including exercise and other physical activity).
• Prevent recurrent exacerbations of chronic conditions and minimize the need for hospitalization or ER visits.
• Prevent recurrence of atrial fibrillation. b. Drug-related: Prevent, minimize, or manage drug-related morbidity.
• Monitor for side effects or toxicity.
• Monitor for drug-drug, drug-disease, and drug-food interactions. Once problems are identified, resolutions must be developed, prioritized, and implemented. Patient or caregiver input is especially helpful at this stage because the individual can describe subjective as well as objective data, expectations or concerns that may be affecting drug therapy, and deficits in drug knowledge, understanding, or administration.
Resolutions may result from numerous strategies, including dose alteration, addition or discontinuation of medication, adjunct medications, regimen adjustment, complementary therapies, instruction on medication administration or devices, disease or medication education, development of "cues" as compliance reminders (e.g., pill boxes), and identification of ways to avoid, detect, or manage side effects or toxicities. Needless to say, the involvement of patients and family or caregivers is critical for successful implementation of most resolution strategies and for optimal disease management.
Because of the extent of B.L.'s medication-related problems and potential interventions (Tables 3 and 4) , it was agreed to tackle first her asthma exacerbations and high blood glucose levels. To this end, B.L. was counseled about the role of maintenance asthma medications versus rescue drugs. The root of her confusion between these agents was easy to understandbecause the prednisone and fluticasone were both called steroids, it seemed likely that the tablets were a cheaper and easier way to take the medicine. Likewise, since albuterol and salmeterol were both called bronchodilators, it seemed that the albuterol was the cheaper way to take the medicine.
Having grasped the concept of asthma prevention, she was willing to convert to a product combining fluticasone and salmeterol (Advair Diskus) for maintenance/prevention and to reserve the albuterol for quick relief of acute symptoms. Free samples of the new product were dispensed, and B.L. was enrolled in the manufacturer's indigent drug program for subsequent supplies.
She was further instructed on the use of a peak flow meter and advised to monitor her readings and symptoms. At the next visit, these data will be used to determine her maximal expiratory effort ("personal best") and to construct an asthma action plan.
B.L.'s insulin was changed to a basal-based regimen utilizing bedtime glargine (Lantus) insulin and premeal lispro (Humalog) insulin. Education was provided on this dosing concept. She and the pharmacist discussed how this regimen can give greater flexibility in dosing, especially for responding to changes in diet, exercise, and disease exacerbations or medications. She was also given an initial supplementary adjustment algorithm (sliding scale) to correct for any temporary elevation of blood glucose. She agreed to test four times daily and to record her blood glucose results, carbohydrate intake, and insulin doses. At the next visit, these data will be used to modify the adjustment algorithm and to construct a prospective algorithm for matching premeal bolus insulin to the anticipated carbohydrate intake (insulin-to-carbohydrate ratio).
The final interventions for this visit were to increase the dose of potassium chloride and change the fluvastatin to atorvastatin (Lipitor) to further reduce B.L.'s LDL cholesterol. Medication education for atorvastatin was provided, and patient questions were answered.
Other medication-related problems and interventions identified for B.L. are listed and briefly discussed in Tables 3 and 4 . For the sake of brevity, these lists are not inclusive nor are all pharmacotherapy issues discussed.
Monitoring for Effectiveness, Side Effects, and Toxicity
The last step in the PWDT process is to develop a plan to evaluate the patient's progress in attaining desired outcomes, therapeutic endpoints, and behavior changes; to assess effectiveness of pharmacotherapy; and to identify side effects, drug interactions, or toxicity issues that need to be addressed.
The monitoring/follow-up component is the most tedious aspect of the PWDT. For each medication or intervention, key parameters must be identified as markers for effectiveness, for side effects, for drug interactions, and for toxicity. In addition, the time frame and process for assessing those parameters must be determined. Finally, the desired range for the parameter must be listed or a "decision point" must be identified to signal that additional action will be required.
It should be noted that only a limited number of parameters are selected for a given patient. For example, it is not necessary to list and monitor for every possible side effect with equal intensity and frequency. Selection of the monitoring parameters is based on the positive effects (efficacy) that are most important to the care of that patient, as well as the adverse effects • Evidence for the routine use of magnesium in diabetes is lacking. However, hypomagnesemia is a risk factor for recurrence of atrial fibrillation and is associated with hypertension, insulin resistance, glucose intolerance, dyslipidemia, increased platelet aggregation, and cardiovascular disease. 6 Addition of a magnesium supplement is warranted in light of the recent exacerbations of asthma, elevated blood glucose, and increased doses of drugs that deplete body magnesium. An added benefit is that this may counter some of the constipation that may occur with the calcium supplement. d. Angiotensin-converting enzyme (ACE) inhibitor
• For most patients >55 years of age with diabetes and hypertension, an ACE inhibitor is indicated. For B.L., however, the use of diltiazem (a nondihydropyridine calcium-channel blocker) addresses several needs with just one agent: angina therapy, hypertension therapy, prevention of recurrence of atrial fibrillation, and prevention of progression of nephropathy. If additional antihypertensive, renal, or cardiac effects are indicated, an ACE inhibitor should be added to the drug regimen. e. Evaluation for possible drug-induced or postmenopausal osteoporosis 3. Wrong drug regimen prescribed/more efficacious drug (or nonpharmacological intervention) possible a. Fluvastatin is inadequate to achieve a 39% reduction in LDL cholesterol. Even at maximal doses (80 mg daily), this agent would be expected to reduce LDL by about 36%. b. Routine twice-daily doses of premixed insulin do not allow for rapid and efficient correction of glycemic excursions. c. Patient has no asthma action plan to guide self-monitoring and self-management of acute or impending exacerbations. d. Fluticasone and salmeterol can be given in a combined product (Advair). e. Nonpharmacological options for lower-extremity edema may improve diuretic response, such as elevation of extremities during the day to reduce swelling and minimize use of diuretic; use of support stockings; limit salt intake if appropriate. f. The use of >120 mg furosemide/day may signal the emergence of diuretic resistance and suggest the need for sequential nephron blockade. 8 However, before adding an agent such as spironolactone (Aldactone) or metolazone (Zaroxolyn), other causes should be ruled out or minimized, such as excessive dietary fluid and sodium intake and the use of sodium-retentive or anti-natriuretic drugs such as prednisone and nonsteroidal anti-inflammatory drugs (NSAIDs). g. Patient is using prednisone and albuterol as sole maintenance and rescue medications for asthma (because of financial constraints). 4. Too much of the correct drug a. Patient is using excessive doses of salmeterol and fluticasone as treatment for asthma exacerbations (at times when she can afford them). 5. Too little of the correct drug a. Potassium chloride supplement 6. Adverse drug reaction/drug allergy None 7. Drug-drug, drug-disease, drug-food interactions 7 a. Systemic corticosteroid therapy, inhaled corticosteroid therapy, loop diuretics in postmenopausal woman: increased risk for development of osteoporosis b. Furosemide, prednisone in diabetes, w/insulin, rosiglitazone: may increase blood glucose (dose-related response), thus diminishing the pharmacodynamic activity of antidiabetes agents c. Albuterol, salmeterol in diabetes, w/insulin, rosiglitazone: sympathomimetics may increase blood glucose via stimulation of ␤2-receptors, leading to increased glycogenolysis and diminished pharmacodynamic activity of antidiabetes agents d. Albuterol, naproxen, prednisone, fluticasone in hypertension: may increase blood pressure (dose-related response) e. Naproxen, prednisone, aspirin w/furosemide: may decrease the diuretic, naturetic effects of furosemide f. Naproxen in hypertension: may increase blood pressure by inhibition of vasodilatory prostaglandins g. Naproxen in diabetes: may increase risk of nephropathy by inhibition of vasodilatory prostaglandins in renal arteries. Chronic or excessive use of NSAIDs should be avoided in diabetes. h. Furosemide, fluticasone, elevated blood glucose levels: additive hypomagnesemic effects i. Furosemide, prednisone, fluticasone, salmeterol, albuterol: additive hypokalemic effects j. Furosemide, prednisone, fluticasone, salmeterol, albuterol w/digoxin: additive hypokalemic effects may lead to increased potential for digoxin toxicity. k. Diltiazem w/digoxin: may elevate digoxin levels. As long as the dose of diltiazem is consistent, dose of digoxin can be titrated to compensate. Risk of AV block l. Rosiglitazone, insulin: edema. Combined use of insulin with rosiglitazone may increase the risk of heart failure or edema. However, discussion with the patient and examination of the record shows that the edema predated the initiation of rosiglitazone, and the edema has not significantly worsened. m. Digoxin with fluvastatin: some HMG CoA reductase inhibitors, including fluvastatin, may increase serum digoxin levels. n. Prednisone, aspirin, naproxen, and potassium chloride in patient with history of anemia: additive potential for adverse gastrointestinal effects, such as gastritis and gastric mucosa injury, and recurrence of anemia o. Aspirin with diltiazem: diltiazem may enhance the antiplatelet effects of aspirin, leading to prolonged bleeding time. 
Frequency
Ongoing by patient; notify provider if bothersome, intolerable, increased frequency, or nonresponsive to quick-acting bronchodilator; assess at every visit.
Baseline and at every visit Baseline and annually or if suspect
Ongoing by patient; notify provider if bothersome or intolerable.
Ongoing by patient; notify provider if noted.
Baseline and at every visit. If patient can be taught to perform home blood pressure monitoring, encourage daily, then weekly, then monthly monitoring when stable.
Baseline and at every visit. If possible, teach patient to perform with each home blood pressure check.
Ongoing by patient; notify provider if bothersome or intolerable. Ongoing by patient; assess at every visit.
Fluticasone/salmeterol combination inhaler
Glargine and lispro
Monitoring: Effectiveness referral was for "diabetes management," her greatest concern at this visit was her asthma exacerbations.
As can be seen in this case, each coexisting disease or coprescribed drug has a domino effect, affecting other diseases or drugs and ultimately affecting quality of life. With input from B.L., the pharmacist clinician was able to develop a PWDT that addresses her diabetes as well as her other health care needs. B.L. was able to leave the health center with a few achievable self-care goals and medication changes that address her acute concerns and with the knowledge and confidence that, at each subsequent visit, additional progress will be made toward her personalized health status goals.
